Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy

Abstract

Recent studies have established the pivotal roles of patient-derived tumour organoids (PDTOs), innovative three-dimensional (3D) culture systems, in various biological and medical applications. PDTOs, as promising tools, have been established and extensively used for drug screening, prediction of immune response and assessment of immunotherapeutic effectiveness in various cancer types, including glioma, ovarian cancer and so on. The overarching goal is to facilitate the translation of new therapeutic modalities to guide personalised immunotherapy. Notably, there has been a recent surge of interest in the co-culture of PDTOs with immune cells to investigate the dynamic interactions between tumour cells and immune microenvironment. A comprehensive and in-depth investigation is necessary to enhance our understanding of PDTOs as promising testing platforms for cancer immunotherapy. This review mainly focuses on the latest updates on the applications and challenges of PDTO-based methods in anti-cancer immune responses. We strive to provide a comprehensive understanding of the potential and prospects of PDTO-based technologies as next-generation strategies for advancing immunotherapy approaches.

Keywords

cancer / immunotherapy / organoids / tumour microenvironment

References

[1] Gupta A, Atanasov AG, Li Y, Kumar N, Bishayee A. Chlorogenic acid for cancer prevention and therapy: current status on efficacy and mechanisms of action. Pharmacol Res. 2022; 186: 106505.

[2] Liu D, Dai X, Ye L, et al. Nanotechnology meets glioblastoma multiforme: emerging therapeutic strategies. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023; 15(1): e1838.

[3] Yang W, Wu H, Tong L, et al. A cuproptosis-related genes signature associated with prognosis and immune cell infiltration in osteosarcoma. Front Oncol. 2022; 12: 1015094.

[4] Fan J, To KKW, Chen Z-S, Fu L. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance. Drug Resist Updates. 2023; 66: 100905.

[5] Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomarker Res. 2023; 11(1): 49.

[6] Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020; 19(1): 160.

[7] Pang K, Shi Z-D, Wei L-Y, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updates. 2023; 66: 100907.

[8] Yiong CS, Lin TP, Lim VY, Toh TB, Yang VS. Biomarkers for immune checkpoint inhibition in sarcomas—are we close to clinical implementation? Biomarker Res. 2023; 11(1): 75.

[9] Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduction and targeted therapy. 2023; 8(1): 160.

[10] Xin X, Yang H, Zhang F, Yang S-T. 3D cell coculture tumor model: a promising approach for future cancer drug discovery. Process Biochem. 2019; 78: 148-160.

[11] Long Y, Xie B, Shen HC, Wen D. Translation potential and challenges of in vitro and murine models in cancer clinic. Cells. 2022; 11(23): 3868.

[12] Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018; 11(1): 116.

[13] Tie J. Tailoring immunotherapy with liquid biopsy. Nat Cancer. 2020; 1(9): 857-859.

[14] Schumacher TN, Scheper W. A liquid biopsy for cancer immunotherapy. Nat Med. 2016; 22(4): 340-341.

[15] Connal S, Cameron JM, Sala A, et al. Liquid biopsies: the future of cancer early detection. J Transl Med. 2023; 21(1): 118.

[16] Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014; 345(6194): 1247125.

[17] Takahashi N, Higa A, Hiyama G, et al. Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy. Oncol Lett. 2021; 21(5): 406.

[18] Su C, Olsen KA, Bond CE, Whitehall VLJ. The efficacy of using patient-derived organoids to predict treatment response in colorectal cancer. Cancers. 2023; 15(3): 805.

[19] Forsythe SD, Sivakumar H, Erali RA, et al. Patient-specific sarcoma organoids for personalized translational research: unification of the operating room with rare cancer research and clinical implications. Ann Surg Oncol. 2022; 29(12): 7354-7367.

[20] Ou L, Liu S, Wang H, et al. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine. 2023; 92: 104614.

[21] Scognamiglio G, De Chiara A, Parafioriti A, et al. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br J Cancer. 2019; 121(11): 979-982.

[22] Tang M, Chen C, Wang G, et al. Evaluation of B7-H3 targeted immunotherapy in a 3D organoid model of craniopharyngioma. Biomolecules. 2022; 12(12): 1744.

[23] Casas-Arozamena C, Cortegoso A, Piñeiro-Perez R, et al. Improving the management of endometrial cancer patients through the use of liquid biopsy analyses: a case report. Int J Mol Sci. 2022; 23(15): 8539.

[24] Forsythe SD, Erali RA, Laney P, et al. Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research. Sci Rep. 2022; 12(1): 13865.

[25] Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009; 459(7244): 262-265.

[26] Yuan B, Zhao X, Wang X, et al. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. Clin Transl Med. 2022; 12(1): e678. doi:10.1002/ctm2.678

[27] Chen Z, Yue Z, Yang K, Li S. Nanomaterials: small particles show huge possibilities for cancer immunotherapy. J Nanobiotechnol. 2022; 20(1): 484.

[28] Klein E, Hau AC, Oudin A, Golebiewska A, Niclou SP. Glioblastoma organoids: pre-clinical applications and challenges in the context of immunotherapy. Front Oncol. 2020; 10: 604121.

[29] Ning R-X, Liu C-Y, Wang S-Q, Li W-K, Kong X. He Z-W. Application status and optimization suggestions of tumor organoids and CAR-T cell co-culture models. Cancer Cell Int. 2024; 24(1): 98.

[30] Tan R, Zhang Z, Ding P, et al. A growth factor-reduced culture system for colorectal cancer organoids. Cancer Lett. 2024; 588: 216737.

[31] Tüysüz N, van Bloois L, van den Brink S, et al. Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells. Nat Commun. 2017; 8(1): 14578.

[32] Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011; 141(5): 1762-1772.

[33] Ren X, Chen W, Yang Q, Li X, Xu L. Patient-derived cancer organoids for drug screening: basic technology and clinical application. J Gastroenterol Hepatol. 2022; 37(8): 1446-1454.

[34] Nishinakamura R. Advances and challenges toward developing kidney organoids for clinical applications. Cell Stem Cell. 2023; 30(8): 1017-1027.

[35] Geyer M, Queiroz K. Microfluidic platforms for high-throughput pancreatic ductal adenocarcinoma organoid culture and drug screening. Front Cell Dev Biol. 2021; 9: 761807.

[36] Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun. 2021; 41(12): 1331-1353.

[37] Baker K. Organoids provide an important window on inflammation in cancer. Cancers. 2018; 10(5): 151.

[38] Hu L-F, Yang X, Lan H-R, Fang X-L, Chen X-Y, Jin K-T. Preclinical tumor organoid models in personalized cancer therapy: not everyone fits the mold. Exp Cell Res. 2021; 408(2): 112858.

[39] Compte M, Nuñez-Prado N, Sanz L, Álvarez-Vallina L. Immunotherapeutic organoids. Biomatter. 2013; 3(1): e23897.

[40] Li Z, Xu H, Yu L, et al. Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clin Transl Med. 2022; 12(7): e970. doi:10.1002/ctm2.970

[41] Sato Y, Bolzenius JK, Eteleeb AM, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018; 3(23): e121062.

[42] Zhang Z, Kong X, Ligtenberg MA, et al. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells. Cell Rep Med. 2022; 3(6): 100655.

[43] Cornel AM, Dunnebach E, Hofman DA, et al. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J Immunother Cancer. 2022; 10(12): e005002.

[44] Della Corte CM, Barra G, Ciaramella V, et al. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. J Exp Clin Cancer Res. 2019; 38(1): 253.

[45] Gao M, Lin M, Moffitt RA, et al. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Br J Cancer. 2019; 120(1): 88-96.

[46] Wang B, Xue Y, Zhai W. Integration of tumor microenvironment in patient-derived organoid models help define precision medicine of renal cell carcinoma. Front Immunol. 2022; 13: 902060.

[47] Xia T, Du WL, Chen XY, Zhang YN. Organoid models of the tumor microenvironment and their applications. J Cell Mol Med. 2021; 25(13): 5829-5841.

[48] Too NSH, Ho NCW, Adine C, Iyer NG, Fong ELS. Hot or cold: bioengineering immune contextures into in vitro patient-derived tumor models. Adv Drug Deliv Rev. 2021; 175: 113791.

[49] Liu L, Yu L, Li Z, Li W, Huang W. Patient-derived organoid (PDO) platforms to facilitate clinical decision making. J Transl Med. 2021; 19(1): 40.

[50] Perreard M, Florent R, Divoux J, et al. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies. BMC Cancer. 2023; 23(1): 223.

[51] D’Angelo A, Shibata K, Tokunaga M, Furutani-Seiki M, Bagby S. Generation of murine tumour-reactive T cells by co-culturing murine pancreatic cancer organoids and peripheral blood lymphocytes. Biochem Biophys Rep. 2022; 32: 101365.

[52] Fujii M, Shimokawa M, Date S, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell. 2016; 18(6): 827-838.

[53] Seino T, Kawasaki S, Shimokawa M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell. 2018; 22(3): 454-467.

[54] Votanopoulos KI, Forsythe S, Sivakumar H, et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. Ann Surg Oncol. 2020; 27(6): 1956-1967.

[55] Meng Q, Xie S, Gray GK, et al. Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. J Immunother Cancer. 2021; 9(11): e003213.

[56] Dijkstra KK, Cattaneo CM, Weeber F, et al. Generation of tumor-reactive t cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018; 174(6): 1586-1598.

[57] Coelho MA, Cooper S, Strauss ME, et al. Base editing screens map mutations affecting interferon-gamma signaling in cancer. Cancer Cell. 2023; 41(2): 288-303.

[58] Chakrabarti J, Koh V, Steele N, et al. Disruption of Her2-induced PD-L1 inhibits tumor cell immune evasion in patient-derived gastric cancer organoids. Cancers. 2021; 13(24): 6158.

[59] Subtil B, Iyer KK, Poel D, et al. Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids. Front Immunol. 2023; 14: 1105244.

[60] Zhou G, Lieshout R, van Tienderen GS, et al. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. Br J Cancer. 2022; 127(4): 649-660.

[61] Chakrabarti J, Holokai L, Syu L, et al. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget. 2018; 9(100): 37439-37457.

[62] Chen J, Na F. Organoid technology and applications in lung diseases: models, mechanism research and therapy opportunities. Front Bioeng Biotechnol. 2022; 10: 1066869.

[63] Ho T, Msallam R. Tissues and tumor microenvironment (TME) in 3D: models to shed light on immunosuppression in cancer. Cells. 2021; 10(4): 831.

[64] Dao V, Yuki K, Lo YH, Nakano M, Kuo CJ. Immune organoids: from tumor modeling to precision oncology. Trends Cancer. 2022; 8(10): 870-880.

[65] Chen S, Schoen J. Air-liquid interface cell culture: from airway epithelium to the female reproductive tract. Reprod Domest Anim. 2019; 54(S3): 38-45.

[66] Sun CP, Lan HR, Fang XL, Yang XY, Jin KT. Organoid models for precision cancer immunotherapy. Front Immunol. 2022; 13: 770465.

[67] Ju X-C, Sun X-Y, Li Y, et al. Generation of vascularized brain organoids to study neurovascular interactions. eLife. 2022; 11: e76707.

[68] Xue Y, Wang B, Tao Y, et al. Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma. Precis Clin Med. 2022; 5(4): pbac028.

[69] Esser LK, Branchi V, Leonardelli S, et al. Cultivation of clear cell renal cell carcinoma patient-derived organoids in an air-liquid interface system as a tool for studying individualized therapy. Front Oncol. 2020; 10: 1775.

[70] Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018; 175(7): 1972-1988. doi:10.1016/j.cell.2018.11.021. e16.

[71] Krysko DV, Demuynck R, Efimova I, Naessens F, Krysko O, Catanzaro E. In vitro veritas: from 2D cultures to organ-on-a-chip models to study immunogenic cell death in the tumor microenvironment. Cells. 2022; 11(22): 3705.

[72] Zhang J, Tavakoli H, Ma L, Li X, Han L, Li X. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. Adv Drug Deliv Rev. 2022; 187: 114365.

[73] Ye W, Luo C, Li C, Huang J, Liu F. Organoids to study immune functions, immunological diseases and immunotherapy. Cancer Lett. 2020; 477: 31-40.

[74] Xie H, Appelt JW, Jenkins RW. Going with the flow: modeling the tumor microenvironment using microfluidic technology. Cancers. 2021; 13(23): 6052.

[75] Ao Z, Cai H, Wu Z, et al. Evaluation of cancer immunotherapy using mini-tumor chips. Theranostics. 2022; 12(8): 3628-3636.

[76] Hong HK, Yun NH, Jeong YL, et al. Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling. Cancer Med. 2021; 10(16): 5589-5598.

[77] Jenkins RW, Aref AR, Lizotte PH, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 2018; 8(2): 196-215. doi:10.1158/2159-8290.cd-17-0833

[78] Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018; 8(2): 216-233. doi:10.1158/2159-8290.cd-17-0915

[79] Maulana TI, Kromidas E, Wallstabe L, et al. Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. Adv Drug Deliv Rev. 2021; 173: 281-305.

[80] Veith I, Nurmik M, Mencattini A, et al. Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip. Cell Rep Med. 2024; 5(5): 101549.

[81] Ding S, Hsu C, Wang Z, et al. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell. 2022; 29(6): 905-917.

[82] Wu Z, Ao Z, Cai H, et al. Acoustofluidic assembly of primary tumor-derived organotypic cell clusters for rapid evaluation of cancer immunotherapy. J Nanobiotechnol. 2023; 21(1): 40.

[83] Ngan Ngo TK, Kuo CH, Tu TY. Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies. Biomicrofluidics. 2023; 17(1): 011501.

[84] Aboulkheyr EH, Bigdeli B, Zhand S, Aref AR, Thiery JP, Warkiani ME. Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells. J Cell Physiol. 2021; 236(5): 3918-3928.

[85] Aboulkheyr EH, Zhand S, Thiery JP, Warkiani ME. Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integr Biol (Camb). 2020; 12(7): 188-197.

[86] Chen SC, Wu PC, Wang CY, Kuo PL. Evaluation of cytotoxic T lymphocyte-mediated anticancer response against tumor interstitium-simulating physical barriers. Sci Rep. 2020; 10(1): 13662.

[87] Park D, Son K, Hwang Y, et al. High-throughput microfluidic 3D cytotoxicity assay for cancer immunotherapy (CACI-IMPACT Platform). Front Immunol. 2019; 10: 1133.

[88] Gopal S, Kwon SJ, Ku B, Lee DW, Kim J, Dordick JS. 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Commun Biol. 2021; 4(1): 893.

[89] Ayuso JM, Truttschel R, Gong MM, et al. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology. 2019; 8(3): 1553477.

[90] Ringquist R, Ghoshal D, Jain R, Roy K. Understanding and improving cellular immunotherapies against cancer: from cell-manufacturing to tumor-immune models. Adv Drug Deliv Rev. 2021; 179: 114003.

[91] Kim D, Wu X, Young AT, Haynes CL. Microfluidics-based in vivo mimetic systems for the study of cellular biology. Acc Chem Res. 2014; 47(4): 1165-1173.

[92] Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020; 52(1): 17-35.

[93] Powley IR, Patel M, Miles G, et al. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. Br J Cancer. 2020; 122(6): 735-744.

[94] Zhou X, Qu M, Tebon P, et al. Screening cancer immunotherapy: when engineering approaches meet artificial intelligence. Adv Sci (Weinh). 2020; 7(19): 2001447.

[95] Cho EJ, Kim M, Jo D, et al. Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival. J Exp Clin Cancer Res. 2021; 40(1): 230.

[96] He A, Huang Y, Cheng W, et al. Organoid culture system for patient-derived lung metastatic osteosarcoma. Med Oncol. 2020; 37(11): 105.

[97] Marcon F, Zuo J, Pearce H, et al. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunology. 2020; 9(1): 1845424.

[98] Graney PL, Zhong Z, Post S, Brito I, Singh A. Engineering early memory B-cell-like phenotype in hydrogel-based immune organoids. J Biomed Mater Res Part A. 2022; 110(8): 1435-1447.

[99] Forsythe SD, Erali RA, Sasikumar S, et al. Organoid platform in preclinical investigation of personalized immunotherapy efficacy in appendiceal cancer: feasibility study. Clin Cancer Res. 2021; 27(18): 5141-5150.

[100] Yeo D, Giardina C, Saxena P, Rasko JEJ. The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics. 2022; 24: 561-576.

[101] Remond MS, Pellat A, Brezault C, Dhooge M, Coriat R. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? ESMO Open. 2022; 7(6): 100638.

[102] Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018; 175(7): 1972-1988. doi:10.1016/j.cell.2018.11.021

[103] Xu D, Wang L, Wieczorek K, et al. Single-cell analyses of a novel mouse urothelial carcinoma model reveal a role of tumor-associated macrophages in response to anti-PD-1 therapy. Cancers. 2022; 14(10): 2511.

[104] Troiani T, Giunta EF, Tufano M, et al. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. Br J Cancer. 2020; 122(12): 1782-1790.

[105] Alieva M, Barrera Román M, de Blank S, et al. BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response. Nat Protoc. 2024; 19(7): 2052-2084.

[106] Di Mascolo D, Varesano S, Benelli R, et al. Nanoformulated zoledronic acid boosts the Vδ2 T cell immunotherapeutic potential in colorectal cancer. Cancers. 2019; 12(1): 104.

[107] Mirza S, Bhadresha K, Mughal MJ, et al. Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: are we there yet? Front Oncol. 2023; 12: 1023565.

[108] Homicsko K. Organoid technology and applications in cancer immunotherapy and precision medicine. Curr Opin Biotechnol. 2020; 65: 242-247.

[109] Ou L, Wang H, Huang H, et al. Preclinical platforms to study therapeutic efficacy of human gammadelta T cells. Clin Transl Med. 2022; 12(6): e814. doi:10.1002/ctm2.814

[110] Raskov H, Orhan A, Christensen JP, Gogenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021; 124(2): 359-367.

[111] Chen X, Wang D, Zhu X. Application of double-negative T cells in haematological malignancies: recent progress and future directions. Biomark Res. 2022; 10(1): 11.

[112] Sun H, Han W, Wen J, Ma X. IL4I1 and tryptophan metabolites enhance AHR signals to facilitate colorectal cancer progression and immunosuppression. Am J Transl Res. 2022; 14(11): 7758-7770.

[113] Liu HY, Wang FH, Liang JM, et al. Targeting NAD metabolism regulates extracellular adenosine levels to improve the cytotoxicity of CD8+ effector T cells in the tumor microenvironment of gastric cancer. J Cancer Res Clin Oncol. 2023; 149(7): 2743-2756.

[114] Xu H, Van der Jeught K, Zhou Z, et al. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Investig. 2021; 131(10): e146832.

[115] Schmidt J, Chiffelle J, Perez MAS, et al. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat Commun. 2023; 14(1): 3188.

[116] Wang W, Yuan T, Ma L, et al. Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors. Adv Sci (Weinh). 2022; 9(22): e2105810.

[117] Newey A, Griffiths B, Michaux J, et al. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. J Immunother Cancer. 2019; 7(1): 309.

[118] Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023; 8(1): 9.

[119] de Vries NL, van de Haar J, Veninga V, et al. gammadelta T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature. 2023; 613(7945): 743-750.

[120] Liu T, Tan J, Wu M, et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells. Gut. 2021; 70(10): 1965-1977.

[121] Shankara Narayanan JS, Hayashi T, Erdem S, et al. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. J Immunother Cancer. 2023; 11(1): e006133.

[122] Yin Q, Yu W, Grzeskowiak CL, et al. Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities. Proc Natl Acad Sci USA. 2021; 118(21): e2016168118.

[123] Westcott PMK, Sacks NJ, Schenkel JM, et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat Cancer. 2021; 2(10): 1071-1085.

[124] Gonzalez-Exposito R, Semiannikova M, Griffiths B, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019; 7(1): 101.

[125] Sui Q, Liu D, Jiang W, et al. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. J Immunother Cancer. 2021; 9(3): e001498.

[126] Guo R, Li W, Li Y, Li Y, Jiang Z, Song Y. Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells. Exp Hematol Oncol. 2022; 11(1): 27.

[127] Yuki K, Cheng N, Nakano M, Kuo CJ. Organoid models of tumor immunology. Trends Immunol. 2020; 41(8): 652-664.

[128] Wang J, Chen C, Wang L, et al. Patient-derived tumor organoids: new progress and opportunities to facilitate precision cancer immunotherapy. Front Oncol. 2022; 12: 872531.

[129] Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019; 474(4): 449-461.

[130] Kumari R, Ouyang X, Wang J, et al. Preclinical pharmacology modeling of chimeric antigen receptor T therapies. Curr Opin Pharmacol. 2021; 61: 49-61.

[131] Wang L, Wu S, He H, et al. CircRNA-ST6GALNAC6 increases the sensitivity of bladder cancer cells to erastin-induced ferroptosis by regulating the HSPB1/P38 axis. Laboratory Investigation. 2022; 102(12): 1323-1334.

[132] Majc B, Novak M, Kopitar-Jerala N, Jewett A, Breznik B. Immunotherapy of glioblastoma: current strategies and challenges in tumor model development. Cells. 2021; 10(2): 265.

[133] Fitzgerald AA, Li E, Weiner LM. 3D culture systems for exploring cancer immunology. Cancers. 2020; 13(1): 56.

[134] Dekkers JF, Alieva M, Cleven A, et al. Uncovering the mode of action of engineered T cells in patient cancer organoids. Nat Biotechnol. 2022; 41(1): 60-69. doi:10.1038/s41587-022-01397-w

[135] Schnalzger TE, de Groot MHP, Zhang C, et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. EMBO J. 2019; 38(12): e100928.

[136] Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023; 12(1): 14.

[137] Chiriaco C, Donini C, Cortese M, et al. Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy. J Exp Clin Cancer Res. 2022; 41(1): 309.

[138] Yu L, Li Z, Mei H, et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin Transl Immunol. 2021; 10(2): e1248.

[139] Song EZ, Wang X, Philipson BI, et al. The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. Mol Ther Oncol. 2022; 27: 288-304.

[140] Li H, Harrison EB, Li H, et al. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun. 2022; 13(1): 2154.

[141] Shen Y, Qiu Y, Duan Z-Q, et al. CD39hi identifies an exhausted tumor-reactive CD8+ T cell population associated with tumor progression in human gastric cancer. Pharmacol Res. 2024; 202: 107122.

[142] Liang S, Zheng R, Zuo B, et al. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. Cell Mol Immunol. 2024; 21(3): 213-226.

[143] Yoon JH, Yoon H-N, Kang HJ, et al. Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells. Mol Ther Oncol. 2024; 32(1): 200777.

[144] Kong D, Kwon D, Moon B, et al. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment. Biomed Pharmacother. 2024; 174: 116436.

[145] Strecker MI, Wlotzka K, Strassheimer F, et al. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. OncoImmunology. 2022; 11(1): 2127508.

[146] Jing R, Scarfo I, Najia MA, et al. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell. 2022; 29(8): 1181-1196.

[147] Li S, Wang CS, Montel-Hagen A, et al. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. Cell Rep. 2023; 42(3): 112241.

[148] Wang Z, McWilliams-Koeppen HP, Reza H, et al. 3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022; 29(4): 515-527.

[149] Wang Y, Gao Y, Niu C, et al. Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor. Cancer Immunol Immunother. 2022; 71(11): 2801-2814.

[150] Zhang Z, Liu Q, Tan J, et al. Coating with flexible DNA network enhanced T-cell activation and tumor killing for adoptive cell therapy. Acta Pharm Sin B. 2021; 11(7): 1965-1977.

[151] Bell HN, Zou W. Beyond the barrier: unraveling the mechanisms of immunotherapy resistance. Annu Rev Immunol. 2024; 42(1). doi:10.1146/annurev-immunol-101819-024752

[152] Cerella C, Dicato M, Diederich M. Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting. Pharmacol Res. 2023; 196: 106914.

[153] Küçükköse E, Heesters BA, Villaudy J, et al. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice. J Immunother Cancer. 2022; 10(12): e005345.

[154] Cao K, Zhang G, Zhang X, et al. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response. Oncoimmunology. 2021; 10(1): 1969075.

[155] Yan Y, Chen X, Wang X, et al. The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer. J Exp Clin Cancer Res. 2019; 38(1): 171.

[156] Koikawa K, Kibe S, Suizu F, et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021; 184(18): 4753-4771.

[157] Kapor S, Santibanez JF. Myeloid-derived suppressor cells and mesenchymal stem/stromal cells in myeloid malignancies. J Clin Med. 2021; 10(13): 2788.

[158] Chen J, Sun HW, Yang YY, et al. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduct Target Ther. 2021; 6(1): 4.

[159] Koh V, Chakrabarti J, Torvund M, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021; 518: 59-71.

[160] Olivera I, Sanz-Pamplona R, Bolanos E, et al. A therapeutically actionable protumoral axis of cytokines involving IL-8, TNFalpha, and IL-1beta. Cancer Discov. 2022; 12(9): 2140-2157.

[161] Ding H, Wang G, Yu Z, Sun H, Wang L. Role of interferon-gamma (IFN-gamma) and IFN-gamma receptor 1/2 (IFNgammaR1/2) in regulation of immunity, infection, and cancer development: iFN-gamma-dependent or independent pathway. Biomed Pharmacother. 2022; 155: 113683.

[162] Ren J, Li N, Pei S, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ–stimulated antitumor immunity. J Clin Investig. 2022; 132(8): e153167.

[163] Sun Y, Revach OY, Anderson S, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023; 615(7950): 158-167. doi:10.1038/s41586-023-05704-6

[164] An HW, Seok SH, Kwon JW, et al. The loss of epithelial Smad4 drives immune evasion via CXCL1 while displaying vulnerability to combinatorial immunotherapy in gastric cancer. Cell Rep. 2022; 41(13): 111878.

[165] Teijeira A, Migueliz I, Garasa S, et al. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. Theranostics. 2022; 12(3): 1373-1387.

[166] Benci JL, Xu B, Qiu Y, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016; 167(6): 1540-1554.

[167] Sun J, Chen F, Wu G. Potential effects of gut microbiota on host cancers: focus on immunity, DNA damage, cellular pathways, and anticancer therapy. ISME J. 2023; 17(10): 1535-1551.

[168] Bonaventura P, Alcazer V, Mutez V, et al. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci Adv. 2022; 8(4): eabj3671.

[169] Suarez-Meade P, Watanabe F, Ruiz-Garcia H, et al. SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models. J Neurooncol. 2023; 161(1): 67-76.

[170] Allen J, Rosendahl Huber A, Pleguezuelos-Manzano C, et al. Colon tumors in enterotoxigenic bacteroides fragilis (ETBF)-colonized mice do not display a unique mutational signature but instead possess host-dependent alterations in the APC gene. Microbiol Spectr. 2022; 10(3): e0105522.

[171] Shelkey E, Oommen D, Stirling ER, et al. Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy. Sci Rep. 2022; 12(1): 9983.

[172] Gao Y, Bi D, Xie R, et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther. 2021; 6(1): 398.

[173] Zou F, Tan J, Liu T, et al. The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity. Mol Ther. 2021; 29(5): 1794-1807.

[174] Hamdan F, Ylösmäki E, Chiaro J, et al. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. J Immunother Cancer. 2021; 9(8): e003000.

[175] Rangsitratkul C, Lawson C, Bernier-Godon F, et al. Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. Mol Ther Oncol. 2022; 24: 507-521.

[176] Aisenbrey EA, Murphy WL. Synthetic alternatives to Matrigel. Nat Rev Mater. 2020; 5(7): 539-551.

[177] Heo JH, Kang D, Seo SJ, Jin Y. Engineering the extracellular matrix for organoid culture. Int J Stem Cells. 2022; 15(1): 60-69. 10.15283/ijsc21190

[178] Kozlowski MT, Crook CJ, Ku HT. Towards organoid culture without Matrigel. Commun Biol. 2021; 4(1): 1387.

[179] Sun L, Jiang Y, Tan H, Liang R. Collagen and derivatives-based materials as substrates for the establishment of glioblastoma organoids. Int J Biol Macromol. 2024; 254: 128018.

[180] Boucherit N, Gorvel L, Olive D. 3D tumor models and their use for the testing of immunotherapies. Front Immunol. 2020; 11: 603640.

[181] Kaur S, Kaur I, Rawal P, Tripathi DM. Vasudevan A. Non-matrigel scaffolds for organoid cultures. Cancer Lett. 2021; 504: 58-66.

[182] Gronholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Patient-derived organoids for precision cancer immunotherapy. Cancer Res. 2021; 81(12): 3149-3155.

[183] Eppler HB, Jewell CM. Biomaterials as tools to decode immunity. Adv Mater. 2020; 32(13): e1903367.

[184] Zhang S, Iyer S, Ran H, et al. Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer. Cancer Discov. 2021; 11(2): 362-383.

[185] Hai J, Zhang H, Zhou J, et al. Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy. Clin Cancer Res. 2020; 26(13): 3431-3442.

[186] Ao Z, Wu Z, Cai H, et al. Rapid profiling of tumor-immune interaction using acoustically assembled patient-derived cell clusters. Adv Sci (Weinh). 2022; 9(22): e2201478.

[187] Wu Z, Ao Z, Cai H, et al. Acoustofluidic assembly of primary tumor-derived organotypic cell clusters for rapid evaluation of cancer immunotherapy. J Nanobiotechnol. 2023; 21(1): 40.

[188] Gong Z, Huang L, Tang X, et al. Acoustic droplet printing tumor organoids for modeling bladder tumor immune microenvironment within a week. Adv Healthc Mater. 2021; 10(22): e2101312.

[189] Saenz del Burgo L, Compte M, Aceves M, et al. Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. J Drug Target. 2015; 23(2): 170-179.

[190] Aliperta R, Welzel PB, Bergmann R, et al. Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. Sci Rep. 2017; 7: 42855.

[191] Kim SE, Yun S, Doh J, Kim HN. Imaging-based efficacy evaluation of cancer immunotherapy in engineered tumor platforms and tumor organoids. Adv Healthc Mater. 2024:e2400475. doi:10.1002/adhm.202400475

[192] Choi S, Choi J, Cheon S, et al. Pulmonary fibrosis model using micro-CT analyzable human PSC–derived alveolar organoids containing alveolar macrophage-like cells. Cell Biol Toxicol. 2022; 38(4): 557-575.

[193] Ferreira N, Kulkarni A, Agorku D, et al. OrganoIDNet: a deep learning tool for identification of therapeutic effects in PDAC organoid-PBMC co-cultures from time-resolved imaging data. Cell Oncol. 2024. doi:10.1007/s13402-024-00958-2

[194] Stüve P, Nerb B, Harrer S, et al. Analysis of organoid and immune cell co-cultures by machine learning-empowered image cytometry. Front Med. 2024; 10: 1274482.

[195] Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021; 39(9): 1190-1201.

[196] Han X, Cai C, Deng W, et al. Landscape of human organoids: ideal model in clinics and research. Innovation. 2024; 5(3): 100620.

[197] Tardito S, Matis S, Zocchi MR, Benelli R, Poggi A. Epidermal growth factor receptor targeting in colorectal carcinoma: antibodies and patient-derived organoids as a smart model to study therapy resistance. Int J Mol Sci. 2024; 25(13): 7131.

[198] LeSavage BL, Zhang D, Huerta-López C, et al. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids. Nat Mater. 2024. doi:10.1038/s41563-024-01908-x

[199] Polak R, Zhang ET, Kuo CJ. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat Rev Cancer. 2024. doi:10.1038/s41568-024-00706-6

[200] Perréard M, Florent R, Divoux J, et al. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies. BMC Cancer. 2023; 23(1): 223.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.